Literature DB >> 28446760

Genetic analysis of the TMEM230 gene in Chinese Han patients with Parkinson's disease.

Chang-He Shi1, Fang Li1,2, Meng-Meng Shi1,2, Zhi-Hua Yang1,2, Cheng-Yuan Mao1,2, Shu-Yu Zhang1, Hui Wang1,2, Yuan Cheng1,2, Jing Yang1, Jun Wu1, Yu-Ming Xu3.   

Abstract

TMEM230 mutations have been recently reported to cause autosomal dominant Parkinson's disease (PD). However, there are limited studies from different ethnic populations to support the role of TMEM230 in sporadic PD. In this study, we performed a comprehensive TMEM230 mutation screening in 550 sporadic PD patients and 560 controls to elaborate the genetic contribution of TMEM230 to sporadic PD. Overall, we did not find any pathogenic mutations in the coding sequence, while we identified four variants (c.68 + 182G > A, c.78A > G, c.552 + 11A > G and c.174 + 11C > T) both in the patients and controls, and c.68 + 182G > A appeared to be associated with an increased risk of PD (odds ratio 1.782, 95% confidence interval 1.035-3.067, p < 0.05). After Bonferroni correction, however, c. 68 + 182G > A had no significant association with sporadic PD (p c = 0.136, p c > 0.05). Thus our results suggest that TMEM230 gene mutations may be rare in Chinese populations, and the variability of TMEM230 gene may not be a main factor for sporadic PD patients in Chinese Han populations. More evidence is still needed to clarify this question.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28446760      PMCID: PMC5430725          DOI: 10.1038/s41598-017-01398-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Parkinson’s disease (PD) is a progressive neurological disorder affecting approximately 1% of individuals above 65 years of age[1]. The typical motor symptoms include resting tremor, muscle rigidity, bradykinesia and postural instability, which result from the selective degeneration of dopaminergic neurons and axonal projections in the substantia nigra. The exact pathogenic mechanism underlying PD is still elusive. Although inherited cases caused by genetic mutations only account for 10% of PD patients, these genetic findings have provided novel insights into the pathogenesis of PD[2]. Recently, accumulating studies have revealed the association between vesicle trafficking and PD, and evidence from genetic studies revealed that mutations in vesicle trafficking-related genes (VPS35, RAB39B, and DNAJC6) were associated with familial PD[3-5]. Recently, TMEM230, a novel gene involved in vesicle trafficking, was identified to be associated with clinically typical, autosomal dominant and Lewy body–confirmed PD. A missense mutation (c.422G > T; p.Arg141Leu) in TMEM230 was first identified in a large pedigree from North American and three other mutations (c.551A > G, c.275A > G, and c.550_552delTAGinsCCCGGG) were also detected in other PD patients. Moreover, c.550_552delTAGinsCCCGGG mutation was found in 7 Chinese familial cases[6]. These results suggested that mutations in TMEM230 gene might be novel genetic causes for PD. However, evidence from recent studies in different populations did not fully conform to these new findings[7-11]. In an effort to further investigate the relationship between TMEM230 and sporadic PD in our population, we performed a comprehensive TMEM230 mutation screening in 550 sporadic PD patients and 560 healthy controls.

Results

We did not identify any pathogenic mutations in the coding region of TMEM230 gene in the PD patients and controls, while we identified three known (c.68 + 182G > A, c.78A > G, c.552 + 11A > G) and one unknown SNPs (c.174 + 11C > T) both in the patients and controls (Table 1). Moreover, c.68 + 182G > A appeared to have significantly different frequencies in two groups (odds ratio [OR] 1.782, 95% confidence interval [CI] 1.035–3.067, p < 0.05). After Bonferroni correction, however, there was no significant difference for c.68 + 182G > A in genotypic distribution between PD patients and controls (p c = 0.136, p  > 0.05).
Table 1

Alternative minor allele frequencies of identified TMEM230 variants.

Position at chr20rs numbercDNAAmino acidAlternative minor allele frequencyPD vs Controls
PDHCOR (95% CI)P*
5112779rs149865687c.68 + 182G > Aintron0.03180.01791.782 (1.035–3.067)0.034
5111596rs745443202c.78A > GLeu26Leu0.00270.00093.055 (0.318–29.320)0.308
5111489novelc.174 + 11C > Tintron0.01720.01431.209 (0.625–2.399)0.572
5100780rs750802038c.552 + 11A > G3′UTR0.00450.00361.273 (0.343–4.727)0.718

*P Value was determined using the Pearson’s χ2 test.

PD: Parkinson’s disease; HC: Healthy control; OR: odds ratio; CI: confidence interval.

Alternative minor allele frequencies of identified TMEM230 variants. *P Value was determined using the Pearson’s χ2 test. PD: Parkinson’s disease; HC: Healthy control; OR: odds ratio; CI: confidence interval.

Discussion

TMEM230 plays a critical role in cellular vesicle dynamics, especially synaptic vesicles. Recently, TMEM230 has been identified as a disease-causing gene in PD. Moreover, the genetic defect of TMEM230 discovered by Deng et al. has proved to impair the movement of vesicles and lead to the failure of α-Synuclein degeneration[6]. Further functional studies also revealed that TMEM230 not only was involved in retromer trafficking and Rab8a-mediated exophagy and classical secretion but also shared a converging pathway with leucine-rich repeat kinase 2 (LRRK2), which provided several lines of evidence for the association between TMEM230 and PD pathogenesis[12]. However, subsequent genetic analysis from different ethics found TMEM230 gene pathogenic mutations were rare both in familial and sporadic PD patients[7-11]. As a result, further genetic investigations are necessary to clarify the role of TMEM230 in PD. In this study, we conducted a comprehensive screening of TMEM230 gene in 550 sporadic patients and 560 controls, and failed to identify any pathogenic mutations in the coding sequence. Our results suggested that TMEM230 gene mutations were rare in Chinese Han PD patients, at least in our population. Besides, we detected 4 variants (c.68 + 182G > A, c.78A > G, c.174 + 11C > T, c.552 + 11A > G) both in the cases and controls, and c.68 + 182G > A might be associated with an increased risk of PD (OR 1.782, 95% CI 1.035–3.067, p < 0.05). After correction for multiple testing, however, allele frequencies of c.68 + 182G > A showed no significant difference in two groups (p  > 0.05), indicating that c.68 + 182G of TMEM230 gene might not confer the risk of sporadic PD in Chinese population. Given the limited patients we included, larger samples are needed to testify the role of the variant c.68 + 182G > A in this disease in case of false-negative results. In conclusion, our results indicate that TMEM230 mutations are rare in Chinese Han patients with sporadic PD. None of the four variants (c.68 + 182G > A, c.78A > G, c.174 + 11C > T, c.552 + 11A > G) have significant association with Chinese sporadic PD. The variability of TMEM230 gene may not be linked to sporadic PD patients in Chinese Han populations. Still, further genetic studies including larger sample sizes from different ethnic groups are required to clarify the pathogenic role of TMEM230 gene in PD.

Methods

Patients

A cohort of 550 Chinese Han sporadic PD patients (mean age, 55.9 ± 15.3 years, Male to Female ratio = 319/231) was collected. All the patients were enrolled from the first affiliated Hospital of Zhengzhou University between 2010 and 2016. All patients were submitted to a standardized neurological examination by two movement disorder specialists, and the diagnosis adopted by the doctors was made according to the criteria of the United Kingdom PD Society Brain Bank. The control group was consisted of 560 age and sex matched healthy individuals (mean age, 53.7 ± 14.9 years, Male to Female ratio = 308/252) from the same geographic areas. The study was approved by the Ethics Committee of First Affiliated Hospital of Zhengzhou University and informed consent was obtained from all the participating subjects. All experiments were performed in accordance with the approved guidelines.

Mutation Analysis

Genomic DNA was extracted from peripheral blood collected from the patients and controls using standard protocols. The entire TMEM230 coding region and exon-intron boundaries were sequenced from genomic DNA. Polymerase chain reaction (PCR) analysis of the TMEM230 gene was carried out using primer pairs described previously[6]. Both cases and controls were genotyped by Sanger sequencing. DNASTAR Lasergene MegAlign (v7.1.0) and Chromas (v2.33) were used to conduct sequence alignment.

Statistical Analysis

We did a case-control study using the data which was detected in PD patients and normal controls. Allele frequencies in case and control subjects were compared using Pearson’s χ2, and we used Bonferroni correction to adjust for multiple testing. We also calculated ORs and 95% CI of minor alleles found in this study. p value of 0.05 was regarded as statistically significant.
  12 in total

1.  Evaluating the role of TMEM230 variants in Parkinson's disease.

Authors:  Hauke Baumann; Simone Wolff; Alexander Münchau; Johann M Hagenah; Katja Lohmann; Christine Klein
Journal:  Parkinsonism Relat Disord       Date:  2016-12-20       Impact factor: 4.891

2.  TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.

Authors:  Ya-Chao He; Pei Huang; Qiong-Qiong Li; Qian Sun; Dun-Hui Li; Tian Wang; Jun-Yi Shen; Sheng-Di Chen
Journal:  Mov Disord       Date:  2016-11-21       Impact factor: 10.338

Review 3.  Defects in trafficking bridge Parkinson's disease pathology and genetics.

Authors:  Asa Abeliovich; Aaron D Gitler
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

4.  Genetic analysis of the TMEM230 gene in Chinese patients with familial Parkinson disease.

Authors:  Hongwei Wu; Xiaosheng Zheng; Zhidong Cen; Fei Xie; You Chen; Xingjiao Lu; Wei Luo
Journal:  Parkinsonism Relat Disord       Date:  2016-12-22       Impact factor: 4.891

5.  MC1R variants in Chinese Han patients with sporadic Parkinson's disease.

Authors:  Chang-He Shi; Hui Wang; Cheng-Yuan Mao; Jing Yang; Bo Song; Yu-Tao Liu; Zhi-Hua Yang; Hai-Yang Luo; Shu-Yu Zhang; Jun Wu; Yu-Ming Xu
Journal:  Neurobiol Aging       Date:  2016-03-03       Impact factor: 4.673

6.  A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease.

Authors:  Alexander Zimprich; Anna Benet-Pagès; Walter Struhal; Elisabeth Graf; Sebastian H Eck; Marc N Offman; Dietrich Haubenberger; Sabine Spielberger; Eva C Schulte; Peter Lichtner; Shaila C Rossle; Norman Klopp; Elisabeth Wolf; Klaus Seppi; Walter Pirker; Stefan Presslauer; Brit Mollenhauer; Regina Katzenschlager; Thomas Foki; Christoph Hotzy; Eva Reinthaler; Ashot Harutyunyan; Robert Kralovics; Annette Peters; Fritz Zimprich; Thomas Brücke; Werner Poewe; Eduard Auff; Claudia Trenkwalder; Burkhard Rost; Gerhard Ransmayr; Juliane Winkelmann; Thomas Meitinger; Tim M Strom
Journal:  Am J Hum Genet       Date:  2011-07-15       Impact factor: 11.025

7.  Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology.

Authors:  Gabrielle R Wilson; Joe C H Sim; Catriona McLean; Maila Giannandrea; Charles A Galea; Jessica R Riseley; Sarah E M Stephenson; Elizabeth Fitzpatrick; Stefan A Haas; Kate Pope; Kirk J Hogan; Ronald G Gregg; Catherine J Bromhead; David S Wargowski; Christopher H Lawrence; Paul A James; Andrew Churchyard; Yujing Gao; Dean G Phelan; Greta Gillies; Nicholas Salce; Lynn Stanford; Ashley P L Marsh; Maria L Mignogna; Susan J Hayflick; Richard J Leventer; Martin B Delatycki; George D Mellick; Vera M Kalscheuer; Patrizia D'Adamo; Melanie Bahlo; David J Amor; Paul J Lockhart
Journal:  Am J Hum Genet       Date:  2014-11-26       Impact factor: 11.025

8.  The Parkinson's disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking.

Authors:  Myung Jong Kim; Han-Xiang Deng; Yvette C Wong; Teepu Siddique; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2017-02-15       Impact factor: 6.150

9.  Identification of TMEM230 mutations in familial Parkinson's disease.

Authors:  Han-Xiang Deng; Yong Shi; Yi Yang; Kreshnik B Ahmeti; Nimrod Miller; Cao Huang; Lijun Cheng; Hong Zhai; Sheng Deng; Karen Nuytemans; Nicola J Corbett; Myung Jong Kim; Hao Deng; Beisha Tang; Ziquang Yang; Yanming Xu; Piu Chan; Bo Huang; Xiao-Ping Gao; Zhi Song; Zhenhua Liu; Faisal Fecto; Nailah Siddique; Tatiana Foroud; Joseph Jankovic; Bernardino Ghetti; Daniel A Nicholson; Dimitri Krainc; Onur Melen; Jeffery M Vance; Margaret A Pericak-Vance; Yong-Chao Ma; Ali H Rajput; Teepu Siddique
Journal:  Nat Genet       Date:  2016-06-06       Impact factor: 38.330

10.  A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism.

Authors:  Simon Edvardson; Yuval Cinnamon; Asaf Ta-Shma; Avraham Shaag; Yang-In Yim; Shamir Zenvirt; Chaim Jalas; Suzanne Lesage; Alexis Brice; Albert Taraboulos; Klaus H Kaestner; Lois E Greene; Orly Elpeleg
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

View more
  4 in total

Review 1.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.

Authors:  Sara Bandres-Ciga; Monica Diez-Fairen; Jonggeol Jeff Kim; Andrew B Singleton
Journal:  Neurobiol Dis       Date:  2020-01-25       Impact factor: 5.996

Review 2.  New Genes Causing Hereditary Parkinson's Disease or Parkinsonism.

Authors:  Andreas Puschmann
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 3.  The Role of TMEM230 Gene in Parkinson's Disease.

Authors:  Hao Deng; Kuan Fan; Joseph Jankovic
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

4.  TMEM230 in Parkinson's disease in a southern Spanish population.

Authors:  Cristina Tejera-Parrado; Silvia Jesús; Adrián López-Ruíz; Dolores Buiza-Rueda; Marta Bonilla-Toribio; Inmaculada Bernal-Bernal; María Teresa Periñán; Laura Vargas-González; Pilar Gómez-Garre; Pablo Mir
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.